These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 36058929)
21. Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Ferro M; Di Lorenzo G; Vartolomei MD; Bruzzese D; Cantiello F; Lucarelli G; Musi G; Di Stasi S; Hurle R; Guazzoni G; Busetto GM; Gabriele A; Del Giudice F; Damiano R; Perri F; Perdona S; Verze P; Borghesi M; Schiavina R; Almeida GL; Bove P; Lima E; Autorino R; Crisan N; Farhan ARA; Battaglia M; Russo GI; Ieluzzi V; Morgia G; De Placido P; Terracciano D; Cimmino A; Scafuri L; Mirone V; De Cobelli O; Shariat S; Sonpavde G; Buonerba C World J Urol; 2020 Jan; 38(1):143-150. PubMed ID: 30993426 [TBL] [Abstract][Full Text] [Related]
22. Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. Mezquita L; Auclin E; Ferrara R; Charrier M; Remon J; Planchard D; Ponce S; Ares LP; Leroy L; Audigier-Valette C; Felip E; Zerón-Medina J; Garrido P; Brosseau S; Zalcman G; Mazieres J; Caramela C; Lahmar J; Adam J; Chaput N; Soria JC; Besse B JAMA Oncol; 2018 Mar; 4(3):351-357. PubMed ID: 29327044 [TBL] [Abstract][Full Text] [Related]
23. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S; JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377 [TBL] [Abstract][Full Text] [Related]
24. [Efficacy of lobaplatin plus S-1 and the predictive value of circulating tumor cell in patients with advanced gastric cancer]. Feng Q; Zhao JR; Zhang AX; Li SL Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):696-702. PubMed ID: 30293397 [No Abstract] [Full Text] [Related]
25. Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC. Liu S; Wu F; Li X; Zhao C; Jia Y; Jia K; Han R; Qiao M; Li W; Yu J; Zhou F; Xiong A; Chen B; Fan J; Ren S; Zhou C Front Oncol; 2021; 11():639947. PubMed ID: 33777802 [TBL] [Abstract][Full Text] [Related]
26. Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. Hadadi A; Smith KE; Wan L; Brown JR; Russler G; Yantorni L; Caulfield S; Lafollette J; Moore M; Kucuk O; Carthon B; Nazha B; Liu Y; Bilen MA Urol Oncol; 2022 Jun; 40(6):271.e9-271.e18. PubMed ID: 35466038 [TBL] [Abstract][Full Text] [Related]
27. Values of applying white blood cell counts in the prognostic evaluation of resectable colorectal cancer. Wu J; Ge XX; Zhu W; Zhi Q; Xu MD; Duan W; Chen K; Gong FR; Tao M; Shou LM; Wu MY; Wang WJ Mol Med Rep; 2019 Mar; 19(3):2330-2340. PubMed ID: 30664202 [TBL] [Abstract][Full Text] [Related]
28. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection]. Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920 [No Abstract] [Full Text] [Related]
29. The PD-1, PD-L1 expression and CD3+ T cell infiltration in relation to outcome in advanced gastric signet-ring cell carcinoma, representing a potential biomarker for immunotherapy. Jin S; Xu B; Yu L; Fu Y; Wu H; Fan X; Wei J; Liu B Oncotarget; 2017 Jun; 8(24):38850-38862. PubMed ID: 28418918 [TBL] [Abstract][Full Text] [Related]
30. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action. Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial. Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354 [TBL] [Abstract][Full Text] [Related]
32. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041 [TBL] [Abstract][Full Text] [Related]
33. M2 macrophage infiltration into tumor islets leads to poor prognosis in non-small-cell lung cancer. Cao L; Che X; Qiu X; Li Z; Yang B; Wang S; Hou K; Fan Y; Qu X; Liu Y Cancer Manag Res; 2019; 11():6125-6138. PubMed ID: 31308749 [No Abstract] [Full Text] [Related]
34. Programmed cell death 1 inhibitor plus chemotherapy vs. chemotherapy in advanced drive-gene-negative non-small-cell lung cancer patients: A real-world study. Li Y; Yang P; Zhou X; Yang X; Wu S Front Surg; 2022; 9():954490. PubMed ID: 36117837 [TBL] [Abstract][Full Text] [Related]
35. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Harada K; Dong X; Estrella JS; Correa AM; Xu Y; Hofstetter WL; Sudo K; Onodera H; Suzuki K; Suzuki A; Johnson RL; Wang Z; Song S; Ajani JA Gastric Cancer; 2018 Jan; 21(1):31-40. PubMed ID: 28801853 [TBL] [Abstract][Full Text] [Related]
36. Converged Rab37/IL-6 trafficking and STAT3/PD-1 transcription axes elicit an immunosuppressive lung tumor microenvironment. Kuo IY; Yang YE; Yang PS; Tsai YJ; Tzeng HT; Cheng HC; Kuo WT; Su WC; Chang CP; Wang YC Theranostics; 2021; 11(14):7029-7044. PubMed ID: 34093869 [No Abstract] [Full Text] [Related]
37. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer]. Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919 [No Abstract] [Full Text] [Related]
38. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. Soyano AE; Dholaria B; Marin-Acevedo JA; Diehl N; Hodge D; Luo Y; Manochakian R; Chumsri S; Adjei A; Knutson KL; Lou Y J Immunother Cancer; 2018 Nov; 6(1):129. PubMed ID: 30470260 [TBL] [Abstract][Full Text] [Related]
39. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis. Zhang S; Li S; Cheng Y Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]